News and Announcements
Phylogica Achieves Milestone in Pharma Collaboration
- Published January 31, 2013 2:39PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
PERTH, AUSTRALIA: January 31, 2013 – Phylogica Ltd (ASX: PYC, XETRA: PH7), a leading Australian peptide drug discovery company, announced today the extension of its collaboration with Janssen Biotech, Inc. and its affiliates (“Janssen”) to discover, develop and commercialise new classes of peptide-drug conjugates derived from Phylogica’s Phylomer® drug discovery platform. Phylogica has received an undisclosed payment for funding additional research associated with the extension of the collaboration.
To read a full ASX announcement, please download the document below.
Company Updates
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Where’s the beef? Blackstone just answered the AI question.
In 1984, a fast food ad asked a question that became a catchphrase. Where’s the beef? Jon Gray, President of Blackstone, used that line this month in front of global LPs. It is the question every capital allocator is asking about AI. Trillions of dollars are going into chips, data centres and power. That is […]
Backed By Leading Investment Groups and Family Offices
